Browse

Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea

Cited 0 time in Web of Science Cited 56 time in Scopus
Authors
Kim, Byeong Gwan; Lee, Dong Ho; Ye, Byong Duk; Lee, Kwang Hyuck; Kim, Beung Wook; Kim, Sang Gyun; Kim, Sang Woo; Kim, Sung Kook; Kim, Jae J; Kim, Hak Yang; Park, Jong Jae; Park, Chang Young; Baik, Gwang Ho; Lee, Yong Chan; Lee, Jun Haeng; Lee, Jin Hyug; Chun, Hoon Jai; Hahm, Ki Baik; Hong, Su Jin; Lee, Sang Woo; Jung, Hyun Chae
Issue Date
2007
Publisher
Wiley-Blackwell
Citation
Helicobacter 2007;12:31-5
Keywords
AdolescentAmoxicillin/therapeutic useAnti-Bacterial Agents/*therapeutic useClarithromycin/therapeutic useDrug Administration ScheduleDrug Therapy, CombinationHelicobacter Infections/*drug therapy*Helicobacter pyloriOmeprazoleProton Pumps/antagonists & inhibitors/*therapeutic useTreatment Outcome
Abstract
BACKGROUND AND AIMS: Although triple combination therapy containing a proton pump inhibitor (PPI) and two antibiotics is considered as a standard regimen for the first-line anti-Helicobacter pylori treatment, there are still debates on the ideal duration of treatment. The aim of this study was to compare the efficacies of 7-day and 14-day PPI-containing triple therapy. MATERIALS AND METHODS: This study was performed in a randomized, multicenter, prospective manner. After upper gastrointestinal endoscopy, H. pylori-infected patients with a gastric ulcer and/or a duodenal ulcer were randomly assigned to a PAC7 group (omeprazole 20 mg or equivalent dose of other PPIs, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days) or to a PAC14 group (the same regimen as the PAC7 group but for 14 days). H. pylori status was evaluated by (13)C urea breath test 5 weeks after anti-ulcer treatment completion. RESULTS: A total of 598 patients were enrolled; 337 were randomized to the PAC7 group and 261 to the PAC14 group. The two groups were comparable in terms of baseline characteristics. The eradication rates of the PAC7 group were not inferior to those of the PAC14 group in both intention-to-treat analysis (71.2% vs. 75.5%) and per-protocol analysis (83.6% vs. 86.6%). Incidences of adverse events were comparable. CONCLUSIONS: Although the 7-day PPI-containing triple anti-H. pylori therapy is not inferior to the 14-day therapy, neither treatment duration provides acceptable eradication rate reaching 90% in per-protocol analysis. New combination regimen with higher efficacy should be developed as a first-line eradication therapy for H. pylori in Korea.
ISSN
1083-4389 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17241298

https://hdl.handle.net/10371/22185
DOI
https://doi.org/10.1111/j.1523-5378.2007.00468.x
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Program in Clinical Pharmacology (협동과정-임상약리학전공)Journal Papers (저널논문_협동과정-임상약리학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse